In biologics development, timing is everything. Engaging a CDMO too late can lead to delays, regulatory gaps, and costly process redesigns. Engaging too early, without a clear development strategy, can slow momentum and inflate budgets.
So when is the right moment to bring a CDMO into your program?
For companies moving from early development toward clinical manufacturing, this decision often determines how smoothly the transition to GMP manufacturing will unfold. At 53Biologics, we frequently work with biotech teams navigating this exact inflection point, aligning development work with future GMP expectations from the outset.
The Risk of Waiting Too Long for Engaging a CDMO
Many biotech companies begin internal development or work with academic labs to generate proof of concept. While this approach is common, problems arise when processes optimized at bench scale are not designed with scalability or GMP compliance in mind.
By the time clinical timelines become urgent, the process may require significant restructuring to meet regulatory standards. This can mean repeating analytical validation, redesigning upstream parameters, or rethinking downstream purification entirely.
Engaging a biologics CDMO during late-stage development helps prevent this scenario. At 53Biologics, our Process Development Services are structured to ensure scalability and regulatory alignment from early phases, minimizing friction when transitioning to GMP manufacturing.
The Ideal Engagement Point: Before Clinical Commitment
The most strategic time to involve a CDMO is typically when:
- A lead candidate has been selected
- Preclinical data is progressing positively
- Clinical manufacturing is anticipated within 12–24 months
At this stage, process optimization can still be implemented without regulatory disruption. Critical decisions regarding protein production platform selection, scale-up strategy, and quality control design can be made proactively rather than reactively.
For example, deciding between microbial production and mammalian production has long-term implications. Microbial systems may offer speed and cost-efficiency, while mammalian systems are required for more complex glycosylated biologics.
53Biologics supports both strategies through its Biologics Production Capabilities, allowing sponsors to define the most suitable platform before GMP commitments are locked in.
Aligning Development with GMP Expectations
One of the most common misconceptions is that GMP considerations can be addressed only once the process is “final.” In reality, GMP manufacturing readiness begins during development.
Key elements that should be aligned early include:
- Definition of Critical Process Parameters
- Analytical method robustness
- Raw material traceability
- Documentation standards
At 53Biologics, development and GMP manufacturing are integrated rather than separated functions. Our GMP Manufacturing Services are designed to ensure that process knowledge generated during development flows directly into compliant clinical production.
This integrated model reduces the risk of rework and shortens the timeline between development completion and GMP batch release.
Technology Transfer: Sooner Means Smoother
Technology transfer is often underestimated. If a CDMO becomes involved only after a process is considered “final,” knowledge gaps can appear. Data may be incomplete, and assumptions made at small scale may not hold during scale-up.
Engaging a CDMO earlier allows:
- Parallel risk assessment
- Early identification of scalability limitations
- Realistic GMP timeline forecasting
At 53Biologics, tech transfer is approached as a structured collaboration phase. Whether supporting microbial fermentation or mammalian cell culture programs, we focus on stabilizing and strengthening the process before it enters full GMP manufacturing.
Strategic Advantages of Early CDMO Engagement
Bringing a CDMO into the program at the right time offers several advantages:
- Reduced regulatory risk
- Improved scalability and batch consistency
- Optimized cost structure
- Faster transition to clinical manufacturing
- Clearer roadmap toward commercialization
In biologics production, early alignment between development and GMP expectations is often what differentiates smooth clinical entry from repeated delays.
So, When Should You Engage a CDMO?
The answer is earlier than most teams initially think. The optimal moment is when your molecule shows clinical promise but before GMP manufacturing becomes urgent.
Engaging a CDMO like 53Biologics during late development ensures that process design, protein production strategy, and regulatory planning evolve together. This proactive approach reduces risk and builds a stronger foundation for clinical and commercial success.
If your biologics program is approaching the transition to GMP manufacturing, now may be the right time to start the conversation.
About 53Biologics:
53Biologics is a Spanish CDMO specialized in decoding biologics production, from DNA to proteins. The company provide services from preclinical development to GMP manufacturing, supporting their clients in getting their biological products to market as quickly as possible.
For more information or to speak with one of our experts email us at [email protected]
